title: Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy.
abstract: Concurrent chemoradiotherapy has become the standard of care for patients with inoperable squamous cell head and neck carcinoma. More recently, induction chemotherapy has been adopted as an approach in the management of these patients. We report the results of a phase II trial associating induction chemotherapy and concomitant chemoradiotherapy in a series of patients with inoperable squamous cell head and neck cancer. Twenty-nine patients with advanced squamous cell carcinoma ineligible for surgery were enrolled. Induction chemotherapy with docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) every 21 days was administered for two cycles. Radiotherapy followed the induction phase. During radiotherapy, docetaxel was administered weekly at the dose of 33 mg/m(2) . Primary end point of the study was feasibility of treatment. Six (18%) patients failed to conclude the treatment schedule. Although response rates in evaluable patients were very high (disease control rate >90%), toxicities were a matter of concern. The reported treatment schedule proved infeasible. However, some modifications in ancillary therapies aimed at exploiting its efficacy could make it practicable.
authors.affiliation: Oncology Unit, Villa Scassi Hospital, ASL3 Genovese, Corso Onofrio Scassi, Genoa, Italy. manlio.mencoboni@fastwebnet.it
authors.forename: M
authors.initials: M
authors.lastname: Mencoboni
authors.forename: F
authors.initials: F
authors.lastname: Grillo-Ruggieri
authors.forename: A
authors.initials: A
authors.lastname: Salami
authors.forename: F
authors.initials: F
authors.lastname: Scasso
authors.forename: L
authors.initials: L
authors.lastname: Rebella
authors.forename: A
authors.initials: A
authors.lastname: Grimaldi
authors.forename: M
authors.initials: M
authors.lastname: Dellepiane
authors.forename: G
authors.initials: G
authors.lastname: Moratti
authors.forename: A
authors.initials: A
authors.lastname: Bruzzone
authors.forename: F
authors.initials: F
authors.lastname: Spigno
authors.forename: R
authors.initials: R
authors.lastname: Ghio
authors.forename: M
authors.initials: M
authors.lastname: Figliomeni
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods; D000077143:Docetaxel; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D012074:Remission Induction / Q000379:methods; D000077195:Squamous Cell Carcinoma of Head and Neck; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin